PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction

BACKGROUND: Cancer therapies inhibiting PI3Kα (phosphoinositide 3‐kinase‐α)–dependent growth factor signaling, including trastuzumab inhibition of HER2 (Human Epidermal Growth Factor Receptor 2), can cause adverse effects on the heart. Direct inhibition of PI3Kα is now in clinical trials, but the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: McLean, Brent A., Patel, Vaibhav B., Zhabyeyev, Pavel, Chen, Xueyi, Basu, Ratnadeep, Wang, Faqi, Shah, Saumya, Vanhaesebroeck, Bart, Oudit, Gavin Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512135/
https://www.ncbi.nlm.nih.gov/pubmed/31039672
http://dx.doi.org/10.1161/JAHA.118.010961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512135/
https://www.ncbi.nlm.nih.gov/pubmed/31039672
http://dx.doi.org/10.1161/JAHA.118.010961

Ejemplares similares